Skip to main content
SpringerLink
Log in

Anlotinib appears to be cost effective as third- or further-line therapy for relapsed SCLC in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The price of anlotinib was $44.49 per 12mg dose, taken from the Chinese national reimbursement list for 2020.

Reference

  • Gong J, et al. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China Advances in Therapy : 21 Aug 2021. Available from: URL: https://doi.org/10.1007/s12325-021-01889-2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anlotinib appears to be cost effective as third- or further-line therapy for relapsed SCLC in China. PharmacoEcon Outcomes News 886, 3 (2021). https://doi.org/10.1007/s40274-021-07981-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-07981-7

Search

Navigation